| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
McArdle Laboratory for Cancer Research, University of Wisconsin Medical School, Madison, Wisconsin 53706
Administration of [3H]aflatoxin B2 (2,3-dihydroaflatoxin B1) (AFB2) to male rats resulted in levels of hepatic DNA- and ribosomal (r)RNA-aflatoxin adducts that were about 1% of those for rats given [3H]aflatoxin B1 (AFB1). The levels of hepatic protein-aflatoxin adducts were 35 to 70% as great for AFB2-treated as compared to AFB1-treated rats.
Mild acid hydrolysis of hepatic DNA and rRNA from rats given [3H]AFB1 or [3H]AFB2 yielded 2,3-dihydro-2,3-dihydroxyaflatoxin B1 and two other major tritiated products that were separable by high-pressure liquid chromatography. With 2-hr hydrolyses approximately 77 and 54% of the 3H from the hepatic DNA of rats given [3H]AFB1 or [3H]AFB2, respectively, and 40 and 32%, respectively, of the 3H from the rRNA of rats given [3H]AFB1 or [3H]AFB2 were isolated as these products. One of the tritiated products was converted to 2,3-dihydro-2,3-dihydroxy-aflatoxin B1 on further mild acid hydrolysis. The high levels of the dihydrodiol and its precursor in the hydrolysates, especially when the 35% loss of added 2,3-dihydro-2,3-dihydroxyaflatoxin B1 under the hydrolysis conditions is taken into account, indicate that aflatoxin B1-2,3-oxide is a major ultimate precursor of the nucleic acid-bound derivatives formed from both AFB1 and AFB2 in rat liver. From these data, AFB2 appears to be converted to AFB1 in the rat liver in vivo to an extent (about 1%) that is comparable to the ratio of hepatocarcinogenicities of these compounds in this species.
The levels of hepatic DNA-bound adducts from [3H]AFB1 were about one-half of the control level in hypophysectomized rats, while the levels of the rRNA- and protein-aflatoxin adducts were similar to those of the controls. The levels of the hepatic macromolecule-bound adducts were 10 to 30% of the control levels in phenobarbital-treated rats. The levels of macromolecule-bound adducts of AFB1 in kidney, spleen, and small intestine were much lower than those of liver. The inhibitory action of phenobarbital on AFB1-induced hepatocarcinogenesis was confirmed; administration of benz(a)anthracene or high levels of ascorbic acid with AFB1 did not alter the tumor incidence.
1 This work was supported by Grant CA-07175, CA-15785, and CRTY-5002 of the National Cancer Institute, USPHS.
2 Present address: Chester Beatty Research Institute, Pollards Wood Research Station, Nightingales Lane, Chalfont St. Giles, Buckinghamshire HP8 4SP, England.
3 Visiting Professor of Oncology, University of Wisconsin, 1975 to 1976 and recipient of USPHS International Research Fellowship 1-F05-TWO-2267. Present address: Department of Biochemistry, College of Medicine, National Taiwan University, Taipel, Taiwan, Republic of China.
4 To whom requests for reprints should be addressed.
Received 8/ 9/76. Accepted 10/13/76.
This article has been cited by other articles:
![]() |
R. E. Sotomayor, M. Washington, L. Nguyen, R. Nyang'anyi, D. M. Hinton, and M. Chou Effects of Intermittent Exposure to Aflatoxin B1 on DNA and RNA Adduct Formation in Rat Liver: Dose-Response and Temporal Patterns Toxicol. Sci., June 1, 2003; 73(2): 329 - 338. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. Preisler, W. J. Caspary, F. Hoppe, R. Hagen, and H. Stopper Aflatoxin B1-induced mitotic recombination in L5178Y mouse lymphoma cells Mutagenesis, January 1, 2000; 15(1): 91 - 97. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Wong and D. Hsieh Aflatoxicol: major aflatoxin B1 metabolite in rat plasma Science, April 21, 1978; 200(4339): 325 - 327. [Abstract] [PDF] |
||||
![]() |
I. Jaitovitch-Groisman, N. Fotouhi-Ardakani, R. L. Schecter, A. Woo, M. A. Alaoui-Jamali, and G. Batist Modulation of Glutathione S-Transferase Alpha by Hepatitis B Virus and the Chemopreventive Drug Oltipraz J. Biol. Chem., October 20, 2000; 275(43): 33395 - 33403. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Cancer Research | Clinical Cancer Research |
| Cancer Epidemiology Biomarkers & Prevention | Molecular Cancer Therapeutics |
| Molecular Cancer Research | Cancer Prevention Research |
| Cancer Prevention Journals Portal | Cancer Reviews Online |
| Annual Meeting Education Book | Meeting Abstracts Online |